Dima Ezmigna

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Paral lel-Group, Event-Driven, Group-Sequential Study with Open-Label Ex tension Period to Assess the Efficacy and Safety of Selexipag as Add- On Treatment to Standard of Care in Children Aged =2 to <18 years with Pulmonary Arterial Hypertension

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add- On Treatment to Standard of Care in Children Aged =2 to <18 years with Pulmonary Arterial Hypertension